Sodium-glucose linked transporter 2 inhibitors reduce serum uric acid in type 2 diabetic mellitus patients with early nephropathy
ObjectiveTo explore the reducing serum uric acid (SUA) effects of dapagliflozin, a sodium-glucose linked transporter 2 (SGLT2) inhibitor in patients with type 2 diabetes mellitus (T2DM) with early nephropathy and hyperuricemia. MethodsSixty-five patients with early T2 diabetic nephropathy and hyperu...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Chinês |
| Publié: |
The editorial office of the Journal of Internal Medicine Concepts & Practice
2025-12-01
|
| Collection: | Neike lilun yu shijian |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.16138/j.1673-6087.2025.05.04 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|